Efficacy and safety of setmelanotide, a melanocortin- 4 receptor agonist, in patients with Bardet-Biedl syndrome and Alstrom syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an openlabel period (vol 10, pg 859, 2022)
LANCET DIABETES & ENDOCRINOLOGY（2023）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined